What are the recommended dosing schedule, monitoring parameters, contraindications, and pregnancy precautions for leflunomide in rheumatoid arthritis?

Leflunomide for Rheumatoid Arthritis

For rheumatoid arthritis, leflunomide should be initiated with a loading dose of 100 mg daily for 3 days, followed by 20 mg daily maintenance therapy, though the loading dose may be omitted in patients at increased risk of hepatotoxicity or hematologic toxicity. 1

Dosing Schedule

Standard Regimen

• Loading dose: 100 mg daily for 3 days 2, 3, 1
• Maintenance dose: 20 mg daily 2, 3, 1
• Dose reduction: May decrease to 10 mg daily if 20 mg is not well tolerated 1

When to Omit Loading Dose

The loading dose should be eliminated in patients at increased risk of adverse events, particularly those:

• Currently receiving methotrexate or other immunosuppressive agents
• Recently discontinued methotrexate or immunosuppressives
• With multiple risk factors for hepatotoxicity 1

This is critical because the loading dose accelerates achievement of steady-state concentrations but increases early toxicity risk. Without loading, steady-state takes approximately 2 months 1.

Monitoring Parameters

Baseline Assessment

• History and physical examination
• Complete blood count (CBC) with differential
• Liver function tests (LFTs)
• Pregnancy test if indicated 2, 3

Ongoing Monitoring Schedule

First 6 months: Monthly CBC with differential and LFTs 2, 3, 4

After 6 months: Every 6-8 weeks (or every 8-12 weeks per ACR 2016 guidelines) 2, 3, 4

Important caveat: Avoid testing LFTs within 2 days after leflunomide administration, as transient elevations may occur 5. The 2022 ACR guidelines for juvenile arthritis recommend every 3-4 months after the initial period, which may inform adult practice 6, 5.

Contraindications

Absolute Contraindications

• Pregnancy (Category X) 2, 3, 2
• Hypersensitivity to leflunomide or its metabolites 2, 3

Relative Contraindications

• Hepatic disease
• Renal disease
• Active serious infections
• Significant immunodeficiency 7

Pregnancy Precautions

Leflunomide is absolutely contraindicated in pregnancy and requires stringent precautions:

Pre-Conception Planning

• Discontinue at least 24 months before conception (per ACR recommendations) 8
• Alternative: Complete cholestyramine washout procedure to accelerate elimination 8

Contraception Requirements

• Both male and female patients must use adequate contraception during treatment and after discontinuation until drug elimination is confirmed 3
• This applies to male patients wishing to father a child 9

If Pregnancy Occurs

1. Immediately discontinue leflunomide
2. Initiate cholestyramine washout: 8 g three times daily for 11 days 1
3. Alternative: Activated charcoal 50 g four times daily for 11 days 1
4. Verify plasma levels of active metabolite (M1) are <0.02 mg/L on two separate tests 14 days apart 1
5. Close monitoring throughout pregnancy 8

Nursing

Leflunomide should not be used by nursing mothers 2, 3, 2

Toxicity Profile and Management

Common Adverse Effects (>10%)

• Diarrhea (27%)
• Nausea (13%)
• Headache (13%)
• Rash (12%)
• Alopecia (9%)
• Weight loss
• Dyspepsia 2, 3, 9

Serious Adverse Effects

Hepatotoxicity (most significant concern):

• Severe liver injury can be fatal
• Most cases occur within 6 months of therapy
• Higher risk in patients with multiple hepatotoxicity risk factors 2, 3
• Management: If ALT >3 times upper limit of normal, temporarily hold leflunomide 6, 5

Hematologic toxicity:

• Pancytopenia, agranulocytosis, thrombocytopenia (rare)
• Higher risk in patients recently treated with methotrexate or other immunosuppressives 2, 3
• Management: Decrease or hold dose if clinically relevant decrease in neutrophils or platelets 6

Other rare but serious:

• Peripheral neuropathy
• Hypertension
• Pneumonitis 10

Drug Interactions

Methotrexate

• No pharmacokinetic interaction between the two drugs
• However, coadministration increases hepatotoxicity risk 2, 3, 2
• Can be used together but requires careful monitoring 10

Rifampin

• Increases leflunomide levels by approximately 40% 2, 3
• Dose adjustment may be necessary

Biologic DMARDs

Recent evidence shows leflunomide can be safely combined with biologics (TNF inhibitors, rituximab) as an alternative to methotrexate 10, 11.

Clinical Efficacy Context

Leflunomide is considered an alternative to methotrexate when methotrexate is contraindicated or not tolerated 7, 12. In the 2014 EULAR guidelines, leflunomide and sulfasalazine are specifically mentioned as alternatives when methotrexate cannot be used 7. The 2022 EULAR update continues to position leflunomide as a first-line csDMARD option alongside methotrexate 11.

Efficacy becomes apparent at 4 weeks, earlier than methotrexate or sulfasalazine, with full effect by 6 months 9. The drug has a very long half-life (~2 weeks), which is both an advantage for once-daily dosing and a disadvantage when adverse effects occur 13, 9.

Key Clinical Pitfalls

1. Do not test LFTs within 48 hours of dosing - transient elevations are common and misleading 5
2. Remember the 2-week half-life - dose adjustments take weeks to show effect; adverse events persist after discontinuation 13
3. Pregnancy planning requires 24 months or active washout - this is non-negotiable 8
4. Consider omitting loading dose in high-risk patients - particularly those on or recently off methotrexate 1
5. Monitor more frequently if combined with methotrexate - hepatotoxicity risk is additive 2, 3